[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"United Therapeutics\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":140},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,45,58,84,117],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100053910","phase-3-study-of-the-efficacy-and-safety-of-inhaled-treprostinil-in-subjects-with-progressive-pulmonary-fibrosis-teton-ppf-100053910",false,"NCT05943535","Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)","A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)","Inclusion Criteria:\n\n1. Subject gives voluntary informed consent to participate in the study.\n2. Subject is ≥18 years of age, inclusive, at the time of signing informed consent.\n3. Subject has radiological evidence of pulmonary fibrosis of \\>10% extent on an HRCT scan in the previous 12 months (confirmed by central review).\n4. Subject has a diagnosis of PPF (other than IPF) that fulfills at least 1 of the following criteria for progression within 24 months of screening despite standard treatment of ILD, as assessed by the Investigator:\n\n   1. Clinically significant decline in % predicted FVC based on ≥10% relative decline\n   2. Marginal decline in % predicted FVC based on ≥5% to \\\u003C10% relative decline combined with worsening of respiratory symptoms\n   3. Marginal decline in % predicted FVC based on ≥5% to \\\u003C10% relative decline combined with increasing extent of fibrotic changes on chest imaging\n   4. Worsening of respiratory symptoms as well as increasing extent of fibrotic changes on chest imaging\n5. FVC ≥45% predicted at Screening (confirmed by central review).\n6. Subjects must be on 1 of the following:\n\n   1. On nintedanib or pirfenidone for ≥90 days prior to Baseline and in the Investigator's opinion, are planning to continue treatment through the study\n   2. Not on treatment with nintedanib or pirfenidone for ≥90 days prior to Baseline and in the Investigator's opinion, not planning to initiate either treatment during the study.\n\n   Concomitant use of both nintedanib and pirfenidone is not permitted.\n7. Subjects treated with immunosuppressive agents (eg, mycophenolate, methotrexate, azathioprine, oral corticosteroids, rituximab) need to be on treatment for at least 120 days prior to Baseline and, in the Investigator's clinical opinion, must be refractory to treatment.\n8. Women of childbearing potential must be non-pregnant (as confirmed by a urine pregnancy test at Screening and Baseline) and non-lactating, and will agree to do 1 of the following:\n\n   1. Abstain from intercourse (when it is in line with their preferred and usual lifestyle)\n   2. Use 2 medically acceptable, highly effective forms of contraception for the duration of the study, and at least 30 days after discontinuing study drug.\n\n   i. Medically acceptable, highly effective forms of contraception can include approved hormonal contraceptives (oral, injectable, and implantable) and barrier methods (such as a condom or diaphragm) when used with a spermicide.\n\n   Women who are successfully sterilized (including hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) or postmenopausal (defined as amenorrhea for at least 12 consecutive months) are not considered to be of reproductive potential.\n9. Males with a partner of childbearing potential must agree to use a condom for the duration of treatment and for at least 48 hours after discontinuing study drug.\n10. In the opinion of the Investigator, the subject is able to communicate effectively with study personnel, and is considered reliable, willing, and likely to be cooperative with protocol requirements, including attending all study visits.\n\nExclusion Criteria:\n\n1. Subject is pregnant or lactating.\n2. Subject has primary obstructive airway physiology (forced expiratory volume in 1 second\u002FFVC \\\u003C0.70 at Screening) or greater extent of emphysema than fibrosis on HRCT (confirmed by central review).\n3. Subject has a diagnosis of IPF.\n4. Subject has shown intolerance or significant lack of efficacy to a prostacyclin or prostacyclin analogue that resulted in discontinuation or inability to effectively titrate that therapy.\n5. Subject has received any PAH-approved therapy, including prostacyclin therapy (epoprostenol, treprostinil, iloprost, or beraprost; except for acute vasoreactivity testing), IP receptor agonists (selexipag), endothelin receptor antagonists, phosphodiesterase type 5 inhibitors (PDE5-Is), soluble guanylate cyclase stimulators, or activin signaling inhibitors (sotatercept) within 60 days prior to Baseline. As needed use of a PDE5-I for erectile dysfunction is permitted, provided no doses are taken within 48 hours prior to any study-related efficacy assessments.\n6. Subject is receiving \\>10 L\u002Fmin of oxygen supplementation by any mode of delivery at rest at Baseline.\n7. Exacerbation of ILD or active pulmonary or upper respiratory infection within 30 days prior to Baseline. Subjects must have completed any antibiotic or steroid regimens for treatment of the infection or acute exacerbation more than 30 days prior to Baseline to be eligible. If hospitalized for an acute exacerbation of ILD or a pulmonary or upper respiratory infection, subjects must have been discharged more than 90 days prior to Baseline to be eligible.\n8. Subject has uncontrolled cardiac disease, defined as myocardial infarction within 6 months prior to Baseline or unstable angina within 30 days prior to Baseline.\n9. Use of any other investigational drug\u002Fdevice or participation in any investigational study in which the subject received a medical intervention (ie, procedure, device, medication\u002Fsupplement) within 30 days prior to Screening. Subjects participating in non-interventional, observational, or registry studies are eligible.\n10. Acute pulmonary embolism within 90 days prior to Baseline.\n11. In the opinion of the Investigator, the subject has any condition that would interfere with the interpretation of study assessments or would impair study participation or cooperation.\n12. In the opinion of the Investigator, life expectancy \\\u003C12 months due to ILD or a concomitant illness.\n13. Subject has received nerandomilast within 60 days prior to Baseline.","ALL","18 Years",{"count":19,"type":20},698,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","Study RIN-PF-305 is designed to evaluate the safety and efficacy of inhaled treprostinil in subjects with progressive pulmonary fibrosis (PPF) over a 52-week period.",[26,27],"Progressive Pulmonary Fibrosis","Interstitial Lung Disease",[29,30,31],"Treprostinil","PPF","ILD","RECRUITING","2026-07-09",{"date":35,"type":36},"2026-07-13","ACTUAL",{"date":38,"type":36},"2023-10-30",{"date":40,"type":20},"2027-11",{"name":42,"class":43},"United Therapeutics","INDUSTRY",165,{"id":46,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":21,"phases":48,"briefSummary":24,"conditions":49,"keywords":50,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":51,"lastUpdatePostDateStruct":52,"startDateStruct":54,"completionDateStruct":55,"leadSponsor":56,"locationsCount":57},"100511753",{"count":19,"type":20},[23],[26,27],[29,30,31],"2026-06-17",{"date":53,"type":36},"2026-06-18",{"date":38,"type":36},{"date":40,"type":20},{"name":42,"class":43},160,{"id":59,"slug":60,"hasResults":11,"nctId":61,"briefTitle":62,"officialTitle":62,"acronym":4,"eligibilityCriteria":63,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":64,"targetDuration":4,"studyType":66,"phases":4,"briefSummary":67,"conditions":68,"keywords":71,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},"100545937","decipher-ild-a-real-world-patient-registry-in-group-3-pulmonary-hypertension-associated-with-interstitial-lung-disease-ph-ild-100545937","NCT06388421","DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)","Inclusion Criteria:\n\n1. Adults aged 18 years or older\n2. Diagnosis of fibrotic ILD based on high-resolution computed tomography imaging, including but not limited to:\n\n   1. Idiopathic interstitial pneumonia, including idiopathic pulmonary fibrosis\n   2. Autoimmune ILD\n   3. Chronic hypersensitivity pneumonitis\n   4. Nonspecific interstitial pneumonia\n   5. Occupational lung disease\n   6. Combined pulmonary fibrosis and emphysema with fibrosis greater than the extent of emphysema on lung imaging as determined by the Investigator\n3. For patients to be eligible for Cohorts 1 to 3: RHC confirmed PH (mean pulmonary artery pressure \\>20 mmHg, pulmonary artery wedge pressure\n\n   ≤15 mmHg, pulmonary vascular resistance \\>2 WU).\n4. For patients to be eligible for Cohort 1, they must not be receiving inhaled treprostinil at Baseline.\n5. For patients to be eligible for Cohort 2, they must have initiated\n\nTyvaso\u002FTyvaso DPI at 1 of the following time points:\n\n1. Baseline\n2. ≤90 days prior to Baseline 6. For patients to be eligible for Cohort 3, they must be receiving Tyvaso\u002FTyvaso DPI at Baseline and for \\>90 days prior to Baseline. 7. For patients to be eligible for Cohort 4: Prior RHC not meeting the definition of PH as described in Inclusion Criterion 3 but has a pulmonary artery wedge pressure ≤15 mmHg. 8. Co-enrollment in other observational or interventional studies is permitted. 9. Patient is willing and able to provide informed consent and complete surveys\u002Fquestionnaires in English or Spanish.\n\nExclusion Criteria:\n\n1. Confirmed diagnosis of Group 1, 2, 4, or 5 PH\n\n   a. In cases in which a patient has a diagnosis of PH-ILD along with a concomitant diagnosis of another PH group (eg, Group 1), enrollment may be permitted at the Investigator's discretion if, in their clinical judgment, PH-ILD is the predominant driver of the patient's PH.\n2. Confirmed diagnosis of Group 3 PH associated with lung diseases and or hypoxia other than fibrotic ILD, as outlined in Inclusion Criterion 2.\n3. Patients receiving inhaled treprostinil (Yutrepia™) at Baseline. Patients receiving other forms of PH therapy will be eligible for enrollment.",{"count":65,"type":20},900,"OBSERVATIONAL","This is a prospective, real world, multicenter, registry of patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) and interstitial lung disease (ILD).",[69,70,27],"Pulmonary Hypertension Due to Lung Diseases and Hypoxia","Pulmonary Hypertension",[72,73,74],"pulmonary hypertension","interstitial lung disease","pulmonary hypertension associated with interstitial lung disease","2026-06-08",{"date":77,"type":36},"2026-06-10",{"date":79,"type":36},"2025-01-23",{"date":81,"type":20},"2030-11-30",{"name":42,"class":43},67,{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":16,"minAge":92,"maxAge":93,"enrollmentInfo":94,"targetDuration":4,"studyType":21,"phases":96,"briefSummary":99,"conditions":100,"keywords":104,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":116},"100610221","phase-1-study-to-evaluate-the-safety-and-efficacy-of-the-ggta1-ko-thymokidney-in-patients-with-esrd-100610221","NCT07224763","Study to Evaluate the Safety and Efficacy of the GGTA1 KO Thymokidney in Patients With ESRD","EXTEND: A Prospective Study to Evaluate the Safety and Efficacy of GGTA1 KO Thymokidney XenoTransplantation in Patients With End-stage Renal Disease (ESRD)","EXTEND","Inclusion Criteria for all Participants (Groups 1 and 2):\n\n1. Provide voluntarily informed consent to participate in the study and for lifetime follow-up.\n2. Have a diagnosis of ESRD at the time of informed consent.\n3. Hemodialysis dependent for a minimum of 6 months and has a functioning arterial-venous fistula\u002Fgraft or permanent catheter at the time of informed consent.\n4. 50 to 70 years of age at the time of informed consent, or 40 to \\\u003C50 years of age with a calculated panel reactive antibody (cPRA) of ≥99.9%.\n5. Evidence of thymic involution on chest computed tomography (CT) scan with a thymic region of interest score of ≤1.\n6. Live within 3 hours travel time of the xenotransplant center.\n7. Female participants must be postmenopausal or permanently sterilized (eg, hysterectomy, bilateral oophorectomy, or bilateral salpingectomy). Male participants must agree to the use of a highly effective method of birth control, if the possibility of conception exists.\n8. Negative xeno-crossmatch at Screening and pre-transplant.\n9. Estimated Post Transplant Survival Calculator score \\>20%.(https:\u002F\u002Foptn.transplant.hrsa.gov\u002Fdata\u002Fallocation-calculators\u002Fepts-calculator\u002F).\n10. Body mass index ≤35 kg\u002Fm2.\n11. Have completed or have initiated and plan to complete (meningococcal A, C, W, Y and meningococcal B vaccine series only) Centers for Disease Control and Prevention-recommended courses of age- and risk-factor-appropriate vaccinations.\n12. Seropositive (immunoglobulin G) for cytomegalovirus and Epstein-Barr virus.\n\nAdditional Inclusion Criteria for Group 1:\n\n1\\. Ineligible for conventional allogeneic kidney transplantation due to medical reason(s) for any of the following:\n\n1. Ineligible for a living donor transplant.\n2. Ineligible for an OPTN kidney transplant waitlist (reason for ineligibility will be collected).\n3. Delisted from OPTN kidney transplant waitlist (reason for delisting will be collected).\n\nAdditional Inclusion Criteria for Group 2:\n\n1. On an OPTN kidney transplant waitlist (active or inactive status).\n2. No approved living kidney donors.\n3. More likely to die or go untransplanted within 5 years than receive a kidney transplant as measured by the Kidney Transplant Decision Aid at the time of informed consent (select United States for \"Choose your state\" field and National average for \"Choose your transplant program\" field; https:\u002F\u002Fwww.srtr.org\u002Ftools\u002Fkidney-transplant-decision-aid\u002F).\n\nExclusion Criteria (pertain to all participants in Groups 1 and 2):\n\n1. Need for multiple organ transplants.\n2. Severe medical co-morbidities including, but not limited to:\n\n   1. Chronic liver disease.\n   2. Advanced cardiovascular disease.\n   3. Severe peripheral vascular disease that limits technical ability to transplant the GGTA1 KO Thymokidney.\n   4. Severe neurologic diseases or conditions that would preclude meaningful recovery or informed consent.\n   5. Oral steroid-dependent airway disorder or chronic pulmonary disease or requires chronic, intermittent, or continuous supplemental oxygen.\n   6. Pulmonary hypertension.\n   7. Uncontrolled diabetes or sequelae of diabetes mellitus including severe non-proliferative diabetic retinopathy.\n   8. Severe neurogenic bladder that requires intermittent catheterization.\n3. ESRD due to hereditary or structural kidney disease.\n4. Active or recently treated malignancy at the time of informed consent.\n5. Non-renal cause of hematological disorders associated with anemia (eg, thalassemia and sickle disease).\n6. Cannot discontinue chronic anticoagulation therapy (low-dose daily aspirin is permissible).\n7. History of major psychiatric disorders with psychiatric hospitalization and\u002For suicidal ideation within 5 years of informed consent.\n8. Being treated for active tuberculosis (TB), have received prophylaxis for positive FDA-approved interferon-gamma release assay, or test positive for TB by FDA-approved interferon-gamma release assay test during Screening.\n9. Nucleic acid test (NAT) positive for hepatitis B virus and\u002For hepatitis C virus, hepatitis B surface antibody (anti-HBs) titer \\\u003C10 mIU\u002FmL unless the participant is determined to be a nonresponder to hepatitis B vaccination (a nonresponder is defined as having an anti-HB titer \\\u003C10 mIU\u002FmL after having completed both the standard vaccine series and a fourth booster dose and\u002For second standard vaccine series), and\u002For positive for human immunodeficiency virus (HIV; HIV-1 and HIV-2 antibody and\u002For NAT).\n10. Not able to independently perform activities of daily life.\n11. Have a history of medical noncompliance that may preclude adherence to the demands and requirements of xenotransplantation (eg, history of substance use disorder \\[SUD\\] within 1 year of informed consent, lack of social support, untreated psychological conditions).","40 Years","70 Years",{"count":95,"type":20},50,[97,98],"PHASE1","PHASE2","The purpose of this study is to evaluate the safety and efficacy of the GGTA1 KO Thymokidney in patients with end-stage renal disease (ESRD) who are either not eligible for conventional allogeneic kidney transplantation (Group 1) or are on an Organ Procurement and Transplantation Network (OPTN) kidney transplant waitlist, but are more likely to die or go untransplanted within 5 years than receive a kidney transplant (Group 2).\n\nThe study consists of xenotransplantation followed by a 24-week Post-transplant Follow-up Period (Part A) to evaluate the efficacy and safety objectives followed by a Long-term Follow-up Period (Part B) to evaluate participant survival, GGTA1 KO Thymokidney survival, and screening for zoonotic infections. Part B will continue for the lifetime of the participant or for 52 weeks following nephrectomy, if required.",[101,102,103],"ESRD (End-Stage Renal Disease)","Kidney Transplantation","Xenotransplantation",[105,106,103,107],"End-stage renal disease","ESRD","GGTA1 KO Thymokidney","2026-05-26",{"date":110,"type":36},"2026-05-27",{"date":112,"type":20},"2026-06",{"date":114,"type":20},"2076-03",{"name":42,"class":43},1,{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":123,"eligibilityCriteria":124,"healthyVolunteers":11,"sex":16,"minAge":92,"maxAge":93,"enrollmentInfo":125,"targetDuration":4,"studyType":21,"phases":126,"briefSummary":127,"conditions":128,"keywords":129,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":139},"100583610","phase-1-study-to-evaluate-the-safety-and-efficacy-of-the-10-ge-xenokidney-in-patients-with-esrd-100583610","NCT06878560","Study to Evaluate the Safety and Efficacy of the 10 GE Xenokidney in Patients With ESRD","EXPAND: A Prospective Study to Evaluate the Safety and Efficacy of the 10 GE Xenokidney in Patients With End-stage Renal Disease (ESRD)","EXPAND","Inclusion Criteria for all Participants (Groups 1 and 2):\n\n1. Provide voluntarily informed consent to participate in the study and for lifetime follow up.\n2. Have a diagnosis of ESRD at the time of informed consent.\n3. Hemodialysis dependent for a minimum of 6 months and has a functioning arterial venous fistula\u002Fgraft or permanent catheter at the time of informed consent.\n4. 50 to 70 years of age at the time of informed consent, or 40 to \\\u003C50 years of a age with a calculated panel reactive antibody (cPRA) of ≥99.9%.\n5. Live withing 3 hours travel time of the xenotransplant center.\n6. Female participants must be postmenopausal or permanently sterilized (eg, hysterectomy, bilateral oophorectomy, or bilateral salpingectomy). Male participants must agree to the use of a highly effective method of birth control, if the possibility of conception exists.\n7. Negative xeno-crossmatch at Screening and pre-transplant.\n8. Estimated Post Transplant Survival Calculator score \\>20% (https:\u002F\u002Foptn.transplant.hrsa.gov\u002Fdata\u002Fallocation-calculators\u002Fepts-calculator\u002F).\n9. Body mass index ≤35 kg\u002Fm2.\n10. Have completed or have initiated and plan to complete (meningococcal A, C, W, Y and meningococcal B vaccine series only) Centers for Disease Control and Prevention recommended courses of age and risk factor appropriate vaccinations.\n11. Seropositive (immunoglobulin G) for cytomegalovirus and Epstein-Barr virus.\n\nAdditional Inclusion Criteria for Group 1:\n\n1\\. Ineligible for conventional allogeneic kidney transplantation due to medical reason(s) for any of the following:\n\n1. Ineligible for a living donor transplant.\n2. Ineligible for an OPTN kidney transplant waitlist (reason for ineligibility will be collected).\n3. Delisted from OPTN kidney transplant waitlist (reason for delisting will be collected).\n\nAdditional Inclusion Criteria for Group 2:\n\n1. On an OPTN kidney transplant waitlist (active or inactive status).\n2. No approved living kidney donors.\n3. More likely to die or go untransplanted within 5 years than receive a kidney transplant as measured by the Kidney Transplant Decision Aid at the time of informed consent (select United States for \"Choose your state\" field and National average for \"Choose your transplant program\" field; https:\u002F\u002Fwww.srtr.org\u002Ftools\u002Fkidney-transplant-decision-aid\u002F).\n\nExclusion Criteria (pertain to all participants in Groups 1 and 2):\n\n1. Need for multiple organ transplants.\n2. Severe medical co-morbidities including, but not limited to:\n\n   1. Chronic liver disease.\n   2. Advanced cardiovascular disease.\n   3. Severe peripheral vascular disease that limits technical ability to transplant the 10 GE Xenokidney.\n   4. Severe neurologic diseases or conditions that would preclude meaningful recovery or informed consent.\n   5. Oral steroid-dependent airway disorder or chronic pulmonary disease or requires chronic, intermittent or continuous supplemental oxygen.\n   6. Pulmonary hypertension.\n   7. Uncontrolled diabetes or sequelae of diabetes mellitus including severe non-proliferative diabetic retinopathy.\n   8. Severe neurogenic bladder that requires intermittent catheterization.\n3. ESRD due to hereditary or structural kidney disease.\n4. Active or recently treated malignancy at the time of informed consent.\n5. Non-renal cause of hematological disorders associated with anemia (eg, thalassemia and sickle disease).\n6. Cannot discontinue chronic anticoagulation therapy (low-dose daily aspirin is permissible).\n7. History of major psychiatric disorders with a psychiatric hospitalization and\u002For suicidal ideation within 5 years of informed consent.\n8. Being treated for active tuberculosis (TB), have received prophylaxis for positive FDA-approved interferon-gamma release assay, or test positive for TB by FDA-approved interferon-gamma release assay test during Screening.\n9. Nucleic acid test (NAT) positive for hepatitis B virus and\u002For hepatitis C virus, hepatitis B surface antibody (anti HBs) titer \\\u003C10 mIU\u002FmL unless the participant is determined to be a nonresponder to hepatitis B vaccination (a nonresponder is defined as having an anti-HBs titer \\\u003C10 mIU\u002FmL after having completed both the standard vaccine series and a fourth booster dose and\u002For second standard vaccine series), and\u002For positive for human immunodeficiency virus (HIV; HIV-1 and HIV-2 antibody and\u002For NAT).\n10. Not able to independently perform activities of daily life.\n11. Have a history of medical noncompliance that may preclude adherence to the demands and requirements of xenotransplantation (eg, history of substance use disorder (SUD) within 1 year of informed consent, lack of social support, untreated psychological conditions).",{"count":95,"type":20},[97,98],"The purpose of this study is to evaluate the safety and efficacy of the 10 GE Xenokidney in patients with ESRD who are either not eligible for conventional allogeneic kidney transplantation (Group 1) or are on an Organ Procurement and Transplantation Network (OPTN) kidney transplant waitlist, but are more likely to die or go untransplanted within 5 years than receive a kidney transplant (Group 2).\n\nThe study consists of xenotransplantation followed by a 24-week Post-transplant Follow up Period (Part A) to evaluate the efficacy and safety objectives followed by a Long-term Follow-up Period (Part B) to evaluate participant survival, 10 GE Xenokidney survival, and screening for zoonotic infections. Part B will continue for the lifetime of the participant.",[101,102,103],[130,105,106,103],"10 GE Xenokidney","2026-03-24",{"date":133,"type":36},"2026-03-27",{"date":135,"type":36},"2025-10-29",{"date":137,"type":20},"2075-10",{"name":42,"class":43},2,""]